Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$64.42 USD

64.42
1,289,582

+1.22 (1.93%)

Updated Aug 28, 2024 04:00 PM ET

After-Market: $64.96 +0.54 (0.84%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.

Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up

Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024. Stock rises in after-hours trading.

Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare

Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare have been highlighted in this Screen of The Week article.

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.67% and 9.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sumit Singh headshot

4 Stocks That Flaunt an Impressive Interest Coverage Ratio

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y

Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.

BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View

BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.

Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales

Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.

Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat

Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024. Stock declines.

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

Perrigo (PRGO) reports mixed second-quarter 2024 results. It cuts total net sales forecasts primarily due to expected lower distribution in U.S. store brand in second-half 2024.

Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.

Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised

Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.

Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat

Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.

JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View

Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.

Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates

Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. Stock rises.

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.